Navigation Links
Novira Therapeutics Completes $25 Million Series A Financing
Date:3/25/2013

DOYLESTOWN, Pa., March 25, 2013 /PRNewswire/ -- Novira Therapeutics, Inc. today announced the completion of its Series A financing after securing $7.5 million from new investor Versant Ventures. This brings the total raised from all investors in the round to $25 million. Versant joins 5AM Ventures and Canaan Partners, which led the first closing of the Series A in August 2012. In conjunction with this investment, Gianni Gromo M.D ., Ph.D., venture partner with Versant Ventures, joined the company's board of directors.

"We believe the addition of Versant bolsters an already strong investor syndicate," said Osvaldo Flores , Ph.D., president and chief scientific officer of Novira. "We also welcome Gianni to our board and believe his extensive industry experience will contribute greatly to our future success. We plan to use these funds to advance development of our hepatitis B virus (HBV) capsid inhibitor lead program toward the clinic and to discover additional HBV drug candidates."

Dr. Gromo added, "Novira's innovative HBV capsid inhibitor program and the company's highly experienced management team made this an attractive investment for Versant. We believe that Novira's approach to HBV capsid inhibition may disrupt pathways involved in virus persistence and has the potential to produce treatments that can cure millions of patients worldwide who are living with chronic HBV infection."

About Hepatitis B

More than 2 billion people worldwide have been infected with HBV at some time in their lives. Adults with a healthy immune system are capable of clearing HBV infection, but newborns, young children and immunocompromised patients frequently become chronically infected. Approximately 400 million people worldwide suffer from chronic HBV infection, with a significant percentage of those individuals dying from long-term complications such as liver cirrhosis or liver cancer. Treatment with nucleotide/nucleoside analogs can effectively suppress viral replication and delay progression of liver disease but does do not typically lead to a sustained virologic response or cure.

About Versant Ventures

Versant Ventures is a leading venture capital firm that specializes in investments in innovative biopharmaceuticals, medical devices and other life science opportunities. Founded in 1999, the firm consists of an experienced team of managing directors committed to helping entrepreneurs build successful companies that impact healthcare and improve quality of life. The firm's successful IPOs include Clovis Oncology, Jazz Pharmaceuticals, Genomic Health, Insulet and Kythera. M&A exits include Amira, LenSX, Acclarent, Cameron Health Ablation Frontiers and Lutonix. In addition to an industry-leading biotech-focused team in Basel, Switzerland and the San Francisco Bay Area, Versant has a presence in two other key geographic locations of Southern California and Minnesota.

For more information visit versantventures.com.

About Novira Therapeutics

Novira Therapeutics, Inc. is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV infection, a global disease with a high level of unmet medical need. Novira's oral drugs target the capsid of the virus and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company's antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors is rarely curative despite lifelong treatment. Capsid inhibitors that feature a new mechanism of action may address the limitations in the effectiveness of HBV therapy.

For more information, visit www.noviratherapeutics.com.

Contacts:

Corporate Contact
Osvaldo Flores , Ph.D.
President, CSO
lflores@noviratherapeutics.com

Media Contacts
David Schull                           
Matt Middleman, M.D.                                   
Russo Partners                                              
T: 212-845-4271                                
T: 212-845-4272
david.schull@russopartnersllc.com
matt.middleman@russopartnersllc.com


'/>"/>
SOURCE Novira Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
2. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
3. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
4. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
5. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
6. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
7. Society for Brain Mapping and Therapeutics endorse President Obamas support for Human Brain Mapping research; nominating him for prestigious Pioneer in Healthcare Policy Award
8. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
9. United Therapeutics Announces Additional $420 Million Share Repurchase Program
10. Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
11. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... business in Hong Kong. , Nerium International is proud to introduce its Age-Defying ... Contour Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products ...
(Date:2/17/2017)... PUNE, India , February 17, 2017 /PRNewswire/ ... research report "Biomarkers Market by Product (Consumables, Service), ... Disorders), Application (Diagnostics Development, Drug Discovery and Development, ... MarketsandMarkets, the market is projected to reach USD ... in 2016, growing at a CAGR of 13.8% ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology:
(Date:2/8/2017)... YORK , Feb. 7, 2017 ... Driven largely by the confluence of organizations, desires ... distaste for knowledge-based systems (password and challenge questions), ... industrial, and government systems. The market is driven ... a demarcation between consumer and enterprise uses cases, ...
(Date:2/7/2017)... BEACH, New York , February 7, 2017 /PRNewswire/ ... known as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" ... identity management and electronic transaction processing services, is pleased ... reorganization of the Company. Effective January 31, ... of the Board of Directors, CEO and President.  An ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):